Schrodinger Inc (SDGR) Stock Price, Quote & News

Company Profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through...

Industry: Health Information Services

Sector: Healthcare

Phone: 212 295 5800

Website: www.schrodinger.com

Address:

1540 Broadway, 24th Floor, New York, United States

Iightning Nov. 21 at 11:57 PM

1ightning® Options Trade Alert (Actionable) | Buy $SDGR Dec 19 $18 Call | Enter: $1.21 Exit: $1.65 | Profit: 36.94% ROI | https://1ightning.com

0 · Reply

luckydirb Nov. 21 at 4:15 PM

$SDGR fire Ramy and hire a real CEO.

1 · Reply

Iightning Nov. 21 at 3:17 AM

1ightning® Options Trade Alert (Actionable) | Buy $SDGR Dec 19 $18 Call | Enter: $1.21 Exit: $1.65 | Profit: 36.94% ROI | https://1ightning.com

0 · Reply

scott52 Nov. 20 at 6:01 PM

$SDGR Yay! New yearly low! The all-time low is $15.85 on December 5, 2022. That's three years. And no return for shareholders. Yes, let's continue with Ramy at the helm. He's killing it. Literally.

1 · Reply

_BreckMiller_ Nov. 20 at 5:53 PM

Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $SDGR $ELBM $RERE $PTON Got it

0 · Reply

BearishCandle Nov. 20 at 4:44 PM

$SDGR wen 20

1 · Reply

Iightning Nov. 20 at 12:41 AM

1ightning® Options Trade Alert (Actionable) | Buy $SDGR Dec 19 $18 Call | Enter: $1.21 Exit: $1.65 | Profit: 36.94% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 8:54 AM

1ightning® Options Trade Alert (Actionable) | Buy $SDGR Dec 19 $18 Call | Enter: $1.21 Exit: $1.65 | Profit: 36.94% ROI | https://1ightning.com

0 · Reply

inflect1on Nov. 12 at 8:48 PM

$SDGR does not look great at all🫣

2 · Reply

scott52 Nov. 11 at 10:07 PM

$SDGR In the penalty box. Major penalty. Aggressive and dangerous resource mismanagement by the CEO.

1 · Reply

Schrödinger to Present at Jefferies London Healthcare Conference

Nov 5, 2025, 10:41 PM EST - 16 days ago

Schrödinger, Inc. (SDGR) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 16 days ago

Schrödinger Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 7:30 AM EDT - 23 days ago

Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger

Oct 22, 2025, 8:30 AM EDT - 4 weeks ago

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

Oct 15, 2025, 8:30 AM EDT - 5 weeks ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 3:05 PM EDT - 2 months ago

Schrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 27, 2025, 8:30 AM EDT - 3 months ago

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Aug 14, 2025, 7:00 AM EDT - 3 months ago

Schrödinger Announces Discontinuation of SGR-2921 Program

Aug 6, 2025, 9:20 PM EDT - 3 months ago

Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 3 months ago

Schrödinger Reports Second Quarter 2025 Financial Results

Jul 25, 2025, 8:30 AM EDT - 4 months ago

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

Jul 18, 2025, 10:25 AM EDT - 4 months ago

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

Jul 17, 2025, 8:00 AM EDT - 4 months ago

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

$Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia$

Jun 27, 2025, 8:00 AM EDT - 5 months ago

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Jun 13, 2025, 1:02 PM EDT - 5 months ago

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Jun 12, 2025, 7:00 AM EDT - 5 months ago

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Jun 6, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

Jun 4, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

Jun 3, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

Jun 1, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 6 months ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 29, 2025, 5:00 PM EDT - 6 months ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

May 29, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

May 29, 2025, 8:00 AM EDT - 6 months ago

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

May 28, 2025, 12:22 PM EDT - 6 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD IBB ILMN NVS

May 27, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

May 26, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

May 25, 2025, 10:00 AM EDT - 6 months ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

May 22, 2025, 12:00 PM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

May 22, 2025, 8:30 AM EDT - 6 months ago

Schrödinger to Present at Jefferies Global Healthcare Conference

May 20, 2025, 11:37 PM EDT - 6 months ago

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

May 20, 2025, 6:30 AM EDT - 6 months ago

Schrödinger Announces CFO Appointment

May 14, 2025, 9:30 AM EDT - 6 months ago

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

May 7, 2025, 5:59 PM EDT - 7 months ago

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 7 months ago

Schrödinger Reports Strong First Quarter 2025 Financial Results

May 5, 2025, 8:30 AM EDT - 7 months ago

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

Apr 28, 2025, 8:00 AM EDT - 7 months ago

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

Apr 23, 2025, 8:30 AM EDT - 7 months ago

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

Apr 14, 2025, 8:00 AM EDT - 7 months ago

Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Apr 12, 2025, 10:26 AM EDT - 8 months ago

Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)

Mar 10, 2025, 8:30 AM EDT - 9 months ago

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

Mar 2, 2025, 1:24 AM EST - 9 months ago

Schrödinger: Still Waiting On A Catalyst

Iightning Nov. 21 at 11:57 PM

1ightning® Options Trade Alert (Actionable) | Buy $SDGR Dec 19 $18 Call | Enter: $1.21 Exit: $1.65 | Profit: 36.94% ROI | https://1ightning.com

0 · Reply

luckydirb Nov. 21 at 4:15 PM

$SDGR fire Ramy and hire a real CEO.

1 · Reply

Iightning Nov. 21 at 3:17 AM

1ightning® Options Trade Alert (Actionable) | Buy $SDGR Dec 19 $18 Call | Enter: $1.21 Exit: $1.65 | Profit: 36.94% ROI | https://1ightning.com

0 · Reply

scott52 Nov. 20 at 6:01 PM

$SDGR Yay! New yearly low! The all-time low is $15.85 on December 5, 2022. That's three years. And no return for shareholders. Yes, let's continue with Ramy at the helm. He's killing it. Literally.

1 · Reply

_BreckMiller_ Nov. 20 at 5:53 PM

Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $SDGR $ELBM $RERE $PTON Got it

0 · Reply

BearishCandle Nov. 20 at 4:44 PM

$SDGR wen 20

1 · Reply

Iightning Nov. 20 at 12:41 AM

1ightning® Options Trade Alert (Actionable) | Buy $SDGR Dec 19 $18 Call | Enter: $1.21 Exit: $1.65 | Profit: 36.94% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 8:54 AM

1ightning® Options Trade Alert (Actionable) | Buy $SDGR Dec 19 $18 Call | Enter: $1.21 Exit: $1.65 | Profit: 36.94% ROI | https://1ightning.com

0 · Reply

inflect1on Nov. 12 at 8:48 PM

$SDGR does not look great at all🫣

2 · Reply

scott52 Nov. 11 at 10:07 PM

$SDGR In the penalty box. Major penalty. Aggressive and dangerous resource mismanagement by the CEO.

1 · Reply

Woodpecker99 Nov. 10 at 11:30 PM

$SDGR haven’t been here in awhile. This stock just goes down still huh

1 · Reply

maizeblue22 Nov. 10 at 7:52 PM

$SDGR should be doing better giving their computational products are used by a lot of early stage biotechs to simulate interactions between drugs and their targets. They have both small molecule and biologic focused software packages that are separate subscriptions (priced at > $50K per year for industry).

1 · Reply

luckydirb Nov. 8 at 8:56 PM

$SDGR should start looking for a new CEO now.

0 · Reply

The300 Nov. 8 at 8:29 PM

$SDGR reversing strategy on becoming a drug developer. This is probably the right call since they have struggled to find compelling programs. Unfortunately, this is now about trying to find path to profitability. less risk but big upside is no longer there. it is what it is.

0 · Reply

Jasooon Nov. 8 at 2:51 AM

$SDGR make no mistake, this is a reset. The management made a mistake in going forward with this strategy, but it takes a lot of self-reflection to realize they were wrong and to go back to what they were successful at. AI will be a huge macro tailwind for them. They have a proven platform for preclinical and it makes sense for them to discover and sell instead. They will always have a nice SaaS business to fund these sells. It just takes an asset to move onto next clinical stage for them to get massive discovery revenue.

2 · Reply

Jasooon Nov. 8 at 2:31 AM

$SDGR This hits hard

0 · Reply

lee305 Nov. 7 at 5:08 PM

$SDGR covering short. Gg

0 · Reply

scott52 Nov. 7 at 4:44 PM

$SDGR My favorite... Not giving any specifics...but we're focused on our profitability profile. This is such a crock of shit. Honestly, given the slowing dodtwy revenue, i think tge stock deserves to trade at 4x software + .75x cash. I'm gonna be generous and say $200M for 2025. That's $800M. Cash x .75x is $300M. So, total nadir valuation of $1.1B. Divide by 74m shares. Bottom is $14.75 give or take.

1 · Reply

Weber10 Nov. 7 at 3:10 PM

$SDGR

0 · Reply

scott52 Nov. 7 at 2:33 PM

$SDGR $16.60 is the yearly low. I fail to see how this avoids a trip into the $16S. And possibly lower. The only saving grace here will be another rate cut as we go into a recession.

0 · Reply

luckydirb Nov. 7 at 1:19 AM

$SDGR is a deeply dei-ed company, say it again. All c officers need to be gone, starting with Ramy.

0 · Reply

scott52 Nov. 6 at 7:13 PM

$SDGR Lots of deal activity around NLRP3. These guys have so many irons in the fire and yet we're being iced out with the stock at all-time lows. Get a fucking deal done. Something. ANYTHING! Neurocrine pens $880M pact with TransThera for immunology target https://share.google/LgfviZClTzLgS9cPW

1 · Reply

Market Cap	1.20B
Revenue (ttm)	207.54M
Net Income (ttm)	-187.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-90.16%
Debt to Equity Ratio	0.00

Volume	1,384,900
Avg Vol	1,158,748
Day's Range	N/A - N/A
Shares Out	73.67M
Stochastic %K	18%
Beta	1.77
Analysts	Strong Sell
Price Target	$26.50